CLCassia Regina Guedes Leal

Cassia Regina Guedes Leal

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Cassia Regina Guedes Leal has a total of 31 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Associação entre o grazing e o grau de ansiedade participantes com esteatose hepática associada à disfunção metabólica.

    by Mariana Saint' Clair Urupúkina, Cinthia Silva Gripp, Grazielle Vilas Bôas Huguenin, Thais Guaraná de Andrade Auler, Letícia de Souza Bottino Rocha, João Pedro de Lacerda Gama Soares, Carmem Ferguson Theodoro, Cássia Regina Guedes Leal

    Associação entre o grazing e o grau de ansiedade participantes com esteatose hepática associada à disfunção metabólica. Introdução: A doença hepática esteatótica associada à disfunção metabólica (MASLD) é uma das doenças mais prevalentes em indivíduos com sobrepeso e obesidade, e a mesma é resultado de fatores ambientais, genéticos, alimentares, comportamentais e psicológicos. Objetivo: Associar o grazing com o grau de ansiedade em participantes com esteatose hepática associada à disfunção metabólica. Método: Realizou-se um estudo observacional do tipo transversal, em indivíduos de ambos os sexos, no qual avaliou-se o comportamento alimentar através do questionário Short Inventory Grazing e o grau de ansiedade através do questionário DASS-21. O estudo foi aprovado pelo Comitê de Ética (CAAE n.º 76629823.2.0000.5243). Os dados foram apresentados como média e desvio padrão ou frequência relativa ou absoluta. E as variáveis categóricas foram analisadas utilizando o teste qui-quadrado. Os valores p ≤ 0,05 foram considerados significativos. Resultado: Observou-se que não houve relação significativa entre o grazing e os graus de ansiedade nos 16 pacientes avaliados (p>0,967) (Tabela 1). Cerca de 50% dos participantes com ansiedade leve apresentaram grazing grave (>8X por semana). Os participantes com ansiedade moderada, 40% mostraram grazing moderado e grave. O comportamento se distribuiu de forma mais equilibrada em pacientes com ansiedade grave (Figura 1). Tabela 1 Relação entre o grazing e o grau de ansiedade. Figura 1 Distribuição entre o grazing e o grau de ansiedade. Legenda: Grau de ansiedade (Normal 0–7, Leve 8–9, Moderada 10–14, Grave 15–19 e Extremamente grave ≥20) e Grazing (Ausência, sem perda de controle e com perda de controle). Conclusão: Não houve uma associação significativa entre o grau de ansiedade e o grazing. As limitações do atual estudo são caracterizadas pelo tamanho amostral reduzido, sendo necessário um número maior, possibilitando explorar de forma mais completa a dinâmica entre o grazing e o grau de ansiedade nos participantes com esteatose hepática associado à disfunção metabólica.

  • Hepatocellular carcinoma surveillance improves early detection and curative treatment in chronic hepatitis C patients treated with direct acting antivirals

    by Cassia Regina Guedes Leal, Carmem Ferguson Theodoro, Thais Guaraná, Jorge Strogoff-De-Matos, Rosângela Teixeira, Renata Perez, Paulo de Tarso Aparecida Pinto, Tatiana Guimaraes, Solange Artimos

  • Open Access

    Incidence and Risk Factors of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C Treated with Direct-Acting Antivirals

    by Cassia Leal, Jorge Strogoff-De-Matos, Carmem Theodoro, Rosangela Teixeira, Renata Perez, Thais Guaraná, Paulo de Tarso Pinto, Tatiana Guimarães, Solange Artimos

    Background: Conflicting data regarding the incidence of hepatocellular carcinoma (HCC) after cure of HCV infection with direct-acting antivirals (DAAs) remains. We investigated the incidence and risk factors to HCC after treatment with DAAs followed up for five years. Methods: A total of 1075 HCV patients ≥ 18 years were treated with DAAs from 2015 to 2019 and followed until 2022. Ultrasonography was performed before DAAs and each 6 months thereafter. Results: Of the total, 51/1075 (4.7%) developed HCC in the median of 40 (IQR 25–58) months: 26/51 (51%) male, median age 60 (IQR 54–66) years, alpha-fetoprotein (AFP) 12.2 (IQR 6.1–18.8) ng/mL, 47/51 (92.1%) cirrhotic 78.7%, 8/51 (15.7%) without sustained virological response (SVR). Seventeen percent had non-characterized nodules before DAAs. Cumulative HCC incidence was 5.9% in 5 years. Overall incidence was 1.46/100 patient-years (PY) (95% CI = 1.09–1.91), being 2.31/100 PY (95% CI = 1.70–3.06), 0.45/100 PY (95% CI = 0.09–1.32) and 0.20/100 PY (95% CI 0.01–1.01) in METAVIR F4, F3 and F2, respectively, and the main risks to HCC were non-characterized nodule, cirrhosis, high AFP values and non-SVR. Conclusion: HCV cure reduced risk for HCC, but it still occurred particularly in cirrhotic patients. Some risk factors can be identified to predict early HCC diagnosis.


  • Open Access

    Hepatocellular Carcinoma Recurrence in HCV Patients Treated with Direct Antiviral Agents

    by Marco Sanduzzi-Zamparelli, Loreto Boix, Cassia Leal, María Reig

    The risk of hepatocellular carcinoma recurrence is universal regardless of the treatment modality applied, and secondary prevention is still an unmet issue even though the elimination of hepatitis C (HCV) with direct antiviral agents (DAAs) was expected to be one of the new options. Unfortunately, the impact of DAAs on hepatocellular carcinoma (HCC) development (de novo and recurrence) is still controversial. Since the first publication on the subject in 2016, almost all groups worldwide have carried out research in this field with hundreds of publications now available. This revision is focused on the impact of DAAs on HCC recurrence and aims to discuss the potential underlying mechanisms and host factors pointing out the time association phenomenon between DAA treatment and HCC recurrence. Moreover, we comment on the methodological issues that could affect the different interpretations of the published results. In conclusion, this is an area of research with potential in the understanding of the impact of factors not previously considered, and may also help change hepatocarcinogenesis tenets, such as the belief that the elimination of HCV should be used as a second prevention treatment.


  • Survival and tolerance to sorafenib in Child-Pugh B patients with hepatocellular carcinoma: a prospective study

    by Cassia Regina Guedes Leal, Cristiane Magalhães, Daniel Barbosa, Diogo Aquino, Bernardo Carvalho, Elizabeth Balbi, Lucio Pacheco, Renata Perez, Paulo de Tarso Pinto, Sérgio Setubal

    Sorafenib has been widely used to treat unresectable hepatocellular carcinoma (HCC) but most studies have been done in Child-Pugh A (CP-A) patients with well-preserved liver function. We evaluated the overall survival (OS) and tolerance to sorafenib in a large cohort of Child-Pugh B (CP-B) HCC patients as compared to CP-A HCC patients. We prospectively studied 130 patients with advanced HCC who started sorafenib between January 2011 and December 2015. Patients were classified as CP-A (n = 65) or CP-B (n = 65). The average OS for all 130 patients was 10 months. CP-A patients had a median survival rate significantly longer than CP-B patients: 12 months vs. 6 months. The OS found in our group of CP-B patients was 6.5 months, which is higher than that found in most studies done so far. When stratified, our CP-B patients had better OS than ever reported. The dose of the drug was interrupted due to adverse events (AEs) in 38 (29%) of the patients, of whom 20 (30%) were CP-A patients and 18 (28%) were CP-B patients. This real-life cohort of CP-B HCC patients treated with sorafenib had a higher survival than that described in the literature, with a satisfactory safety profile. Despite the high prevalence of severe AEs in CP-B patients, there were fewer treatment interruptions in this group, indicating that Child-Pugh B patients can tolerate treatment and may benefit from sorafenib.